From: Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study
 | At inclusion (M0) | At month 3 | At month 6 | P |
---|---|---|---|---|
Biochemical parameters | ||||
 Hemoglobin (g/dL) | 11.13 ± 1.05 | 11.30 ± 1.09 | 11.00 ± 1.16 | 0.54 |
 TSAT (%) | 41.47 ± 22.37 | 29.27 ± 10.88 | 32.58 ± 13.63 | 0.01 |
 Serum ferritin (μg/L) | 947.71 ± 1056.42 | 672.93 ± 490.16 | 570.73 ± 424.41 | 0.0001 |
 Parathyroid hormone (pg/mL) | 188.03 ± 154.67 | ND | 212.73 ± 176.85 | 0.27 |
 β2-microglobuline (mg/L) | 25.88 ± 7.77 | 22.96 ± 5.57 | 21.80 ± 6.53 | 0.00001 |
 C-reactive protein (mg/L) | 14.59 ± 27.10 | 9.04 ± 10.14 | 11.81 ± 30.60 | 0.64 |
 Serum albumin (g/L) | 35.07 ± 4.52 | 37.34 ± 2.99 | 40.02 ± 4.58 | 0.0002 |
Treatment | ||||
 ESA (μg/28 days) | 126.4 ± 91.9 | 109.63 ± 101.03 | 108.20 ± 112.70 | 0.07 |
 Iron supplementation (mg/week) | 77.78 ± 87.62 | 15.56 ± 42.40 | 24.44 ± 52.90 | 0.0003 |